Oral Curcumin Supplementation in Middle-Aged and Older Adults Improves Vascular Function

Vascular Aging Clinical Trial

Official title:

Clinical Translation of Curcumin Therapy to Treat Arterial Aging

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01968564
• Other study ID #: B6398
• Status: Active, not recruiting
• Phase: N/A
• First received: October 19, 2013
• Last updated: March 17, 2017
• Start date: June 2013
• Est. completion date: June 2017

Study information

• Verified date: March 2017
• Source: University of Colorado, Boulder
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed study will assess the ability of curcumin, the active ingredient in the Indian spice tumeric, to improve the function of arteries with age. Overall, the proposed research project has the long-term potential to influence clinical practice guidelines by establishing a novel, easy to deliver, cost-effective therapy for treating age-associated arterial dysfunction and reducing the risk of cardiovascular disease with age.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 118
• Est. completion date: June 2017
• Est. primary completion date: June 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 45 Years to 80 Years

Eligibility

Inclusion Criteria:

• women must be postmenopausal

• body mass index (BMI) <40 kg/m2

• weight stable in the prior 3 months

• absence of clinical disease as determined by medical history, physical examination, blood and urine chemistries, ankle-brachial index, and a graded exercise stress test with monitoring of blood pressure and 12-lead ECG

Related Conditions & MeSH terms

• Vascular Aging

Intervention

Drug:
• Placebo pill
sugar and other inert substances
• High-dose curcumin pill
2000mg curcumin pill/day
• Low-dose curcumin pill
500mg curcumin pill/day

Locations

Country	Name	City	State
United States	University of Colorado Boulder, Clinical Translational Research Center	Boulder	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
University of Colorado, Boulder

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Arterial Stiffness	Arterial pulse wave velocity	12 weeks
Primary	Nitric-oxide mediated endothelium-dependent dilation	flow-mediated dilation and forearm blood flow responses to acetylcholine in the presence and absence of N'-monomethyl-L-arginine	12 weeks
Secondary	Systemic oxidative stress and inflammation	circulating markers of oxidative stress and inflammation	12 weeks
Secondary	Endothelial cell oxidative stress and inflammation	inflammatory and oxidative stress markers in biopsied vascular and arterial endothelial cells	12 weeks

External Links

•   Description of our Research and Laboratory